Literature DB >> 6744035

Evaluation of 4-aminopyridine and 3,4-diaminopyridine penetrability into cerebrospinal fluid in anesthetized rats.

M Lemeignan, H Millart, D Lamiable, J Molgo, P Lechat.   

Abstract

4-aminopyridine (4-AP) and 3,4-diaminopyridine (3,4-DAP) when injected intracisternally to anesthetized rats induced qualitatively similar central nervous system stimulant and convulsant effects at equimolar concentrations. Overall penetrability into cerebrospinal fluid of 4-AP is significantly higher than that of 3,4-DAP after single i.v. administration as evaluated by a high-performance liquid chromatographic determination. The present results can account for the lower central nervous system toxicity of 3,4-DAP when compared to 4-AP previously described after systemic administration.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6744035     DOI: 10.1016/0006-8993(84)90875-8

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  12 in total

1.  Lycopodium clavatum exine microcapsules enable safe oral delivery of 3,4-diaminopyridine for treatment of botulinum neurotoxin A intoxication.

Authors:  T L Harris; C J Wenthur; A Diego-Taboada; G Mackenzie; T S Corbitt; K D Janda
Journal:  Chem Commun (Camb)       Date:  2016-03-18       Impact factor: 6.222

2.  Clinically Relevant Levels of 4-Aminopyridine Strengthen Physiological Responses in Intact Motor Circuits in Rats, Especially After Pyramidal Tract Injury.

Authors:  Anil Sindhurakar; Asht M Mishra; Disha Gupta; Jennifer F Iaci; Tom J Parry; Jason B Carmel
Journal:  Neurorehabil Neural Repair       Date:  2017-01-20       Impact factor: 3.919

3.  Naltrexone potentiates 4-aminopyridine seizures in the rat.

Authors:  A Mihály; K Bencsik; T Solymosi
Journal:  J Neural Transm Gen Sect       Date:  1990

Review 4.  3,4-Diaminopyridine, an orphan drug, in the symptomatic treatment of Lambert-Eaton myasthenic syndrome.

Authors:  J Molgó; J M Guglielmi
Journal:  Pflugers Arch       Date:  1996       Impact factor: 3.657

5.  Update on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridine.

Authors:  Sabine Lindquist; Martin Stangel
Journal:  Neuropsychiatr Dis Treat       Date:  2011-05-30       Impact factor: 2.570

6.  Voltage-Sensitive K(+) Channels Inhibit Parasympathetic Ganglion Transmission and Vagal Control of Heart Rate in Hypertensive Rats.

Authors:  Torill Berg
Journal:  Front Neurol       Date:  2015-12-08       Impact factor: 4.003

Review 7.  Ultrafast and Slow Cholinergic Transmission. Different Involvement of Acetylcholinesterase Molecular Forms.

Authors:  Yves Dunant; Victor Gisiger
Journal:  Molecules       Date:  2017-08-04       Impact factor: 4.411

8.  Multiple sclerosis and the blood-central nervous system barrier.

Authors:  Alan M Palmer
Journal:  Cardiovasc Psychiatry Neurol       Date:  2013-01-15

9.  4-aminopyridine does not enhance flocculus function in tottering, a mouse model of vestibulocerebellar dysfunction and ataxia.

Authors:  John S Stahl; Zachary C Thumser
Journal:  PLoS One       Date:  2013-02-25       Impact factor: 3.240

10.  Use-dependent potentiation of voltage-gated calcium channels rescues neurotransmission in nerve terminals intoxicated by botulinum neurotoxin serotype A.

Authors:  Phillip H Beske; Katie M Hoffman; James B Machamer; Margaret R Eisen; Patrick M McNutt
Journal:  Sci Rep       Date:  2017-11-20       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.